Skip to main content


Browse the articles below to learn more about our faculty’s latest achievements, awards and honors.

  • 06.18.2024
    Edward M. Schaeffer, MD, PhD, outlines Northwestern Medicine's strategic growth in urology and healthcare administration, highlighting partnerships and expansions over the past decade. Under his leadership since 2015, the department has established a robust team of 18 urologists across 8 sites within an 11-hospital system serving Chicagoland, integrating quality standards, education, and marketing to ensure consistent, high-quality care across geographic regions
  • 06.12.2024
    A dysfunctional enzyme may lead to nonalcoholic fatty liver disease in mice, according to a study published in Science Advances.
  • 05.24.2024
    Patients with metastatic urothelial cancer and increased expression of the NECTIN4 gene had a dramatically better response to antibody treatment than patients with reduced gene expression, according to recent findings published in the Journal of Clinical Oncology.
  • 05.07.2024
    Joshua Meeks, MD, PhD, and other experts delve into the key takeaways and groundbreaking highlights from the 2024 American Urological Association Annual Meeting. 
  • 05.06.2024
    Kristin Smith, Fertility Preservation Patient Navigator at Lurie Cancer Center, provided valuable insights into fertility challenges for cancer patients as the keynote speaker at the National Comprehensive Cancer Network’s Oncology Policy Summit. The summit focused on addressing sexual and reproductive health concerns that can impact individuals with cancer both during and after treatment.
  • 05.04.2024
    Joshua J. Meeks, MD, PhD, provides a comprehensive overview of a session held at the 2024 American Urological Association Annual Meeting titled, "Leveraging Innovation in Bladder Cancer Care: Expert Tactics for Successfully Integrating Contemporary Therapeutic Advances Throughout the Disease Spectrum."
  • 04.08.2024

    Adam B. Murphy, MD, MBA, MSCI, offers expert commentary and insight on a recent study highlighting the association between prostate cancer and disparities in vascular health between Black and white men.

  • 03.21.2024
    Edward M. Schaeffer, MD, PhD, explores the latest developments and future prospects of PSMA-PET technology in the realm of prostate cancer diagnosis and treatment. With his vast knowledge and scholarly contributions to the field, Dr. Schaeffer provides invaluable insights into the evolving role of PSMA-PET imaging, highlighting its potential to revolutionize the way prostate cancer is detected, staged, and managed. 
  • 03.18.2024
    Two methods of prostate cancer biopsy demonstrated similar, minimal rates of infection in patients with prostate cancer, according to a recent Northwestern Medicine study published in the journal European Urology.
  • 03.04.2024
    Adam B. Murphy, MD, MBA, MSCI, delves into the pivotal findings and essential insights gleaned from the study titled "Development and validation of a prostate biopsy risk calculator in Black Men," where he assumed the role of senior author. Dr. Murphy sheds light on the significance of the research outcomes and their implications, offering valuable perspectives on the development and validation process of a prostate biopsy risk calculator tailored specifically for Black men.
  • 02.28.2024
    Joshua Meeks, MD, PhD, discuss the ongoing BCG shortage affecting bladder cancer treatment, tracing its roots to production issues in 2012 and increased demand following guideline changes in 2016. He highlight the growing use of Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its availability and proven effectiveness. The conversation also explores the BRIDGE trial, a critical study evaluating the efficacy of Gem/Doce, as well as several large trials investigating checkpoint inhibitors as potential alternatives to BCG.
  • 02.27.2024
    Peter N. Tsambarlis, MD, discusses regenerative therapies for erectile dysfunction, providing an overview and addressing common patient inquiries about these treatments for ED.
  • 02.23.2024
    Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer — its hunger for cholesterol — and how to sneakily use that to destroy it.
  • 02.15.2024
    Increased expression of specific genes in prostate cancer patients may predict whether or not the cancer will respond well to hormone therapy, according to a new study published in Nature Communications.
  • 02.06.2024
    Robert Brannigan, MD, Kristin Smith, and Joshua A. Halpern, MD, MS, engage in a comprehensive discussion regarding the innovative oncofertility program at Northwestern University. As pioneers in the field, Dr. Brannigan and his esteemed colleagues shed light on the multidisciplinary approach adopted by the program, which aims to address the unique reproductive concerns of cancer patients. Through their expertise in urology, oncology, and reproductive endocrinology, they explore the latest advancements and personalized strategies for preserving fertility in individuals undergoing cancer treatment. 
  • 02.02.2024
    During a discussion with CancerNetwork® at the 2024 Genitourinary Cancers Symposium, Joshua Meeks, MD, PhD, Associate Professor of Urology, Biochemistry, and Molecular Genetics, as well as the Section Chief of Robotic Surgery at the Jesse Brown VA Medical Center, shared insights from his presentation on the current BCG shortage. He highlighted potential strategies for oncologists facing this scarcity, such as considering gemcitabine/docetaxel or cystectomy as alternative approaches to manage the disease when BCG supplies are limited.
  • 02.01.2024
    Adam Murphy, MD, MBA, MSCI, discusses the heightened risk of prostate cancer among Black men. Dr. Murphy delves into the various factors contributing to this increased vulnerability, such as genetic predispositions, socioeconomic disparities, and healthcare access issues. Dr. Murphy emphasizes the importance of addressing these factors to reduce the disproportionate impact of prostate cancer on Black men and advocates for tailored strategies in screening, prevention, and treatment.
  • 01.29.2024
    Hiten Patel. MD, MPH, discusses into his team's study, exploring the utilization of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer. Motivated by observed low utilization rates in practice, the research aims to unravel the elective and eligibility factors influencing the application of this treatment.
  • 01.25.2024
    In the wake of public figures like Lloyd Austin and Ryne Sandberg confronting the challenges of prostate cancer, Shailajit Kundu, MD, takes part in an insightful conversation with NBC Chicago's Lauren Petty to provides a comprehensive exploration of the complexities surrounding prostate cancer. Dr. Kundu discusses the advancements in treatment of prostate cancer, the importance of early detection, and the impact on both patients and their communities. 
  • 01.22.2024
    In a recent interview with Urology Times, Vikas Desai, MD delves into the forefront of advancements in treatments for incontinence and Overactive Bladder (OAB). Dr. Desai provides insightful commentary on the latest breakthroughs, showcasing the ongoing progress in urological care. From innovative therapies to emerging technologies, the discussion offers a comprehensive overview of the dynamic landscape in addressing incontinence and OAB.
  • 01.05.2024
    In a discussion about the management of low-risk prostate cancer through active surveillance, Dr. Catalona undergoes a notable shift in perspective.  Initially opposed to active surveillance, he has since adjusted his views, preferring a more conservative approach. This discussion centers on this shift in mindset and its impact on the approach to active surveillance in low-risk prostate cancer cases.
  • 12.25.2023
    As the year wraps up, Urology Times rolls out their top 10 urologic imaging stories of 2023. View highlights as they revisit articles exploring cutting-edge imaging agents in Urology, with standout contributions from the brilliant minds at Northwestern Urology.
  • 12.20.2023
    A team of Northwestern Medicine investigators, including Joshua Meeks, MD, PhD, has identified localized molecular mechanisms associated with a genetic mutation prevalent in various cancers. This discovery holds potential as a biomarker for enhanced patient stratification and treatment. The study points towards promising prospects for developing personalized cancer treatments tailored to the specific genetic alterations found at the tumor site.
  • 11.29.2023
    In a conversation with CancerNetwork® during the 2023 Society of Urologic Oncology (SUO) Annual Meeting, William J. Catalona, MD, underscores the crucial need for genetic studies in prostate cancer. Dr. Catalona emphasizes the importance of advancing understanding and developing robust guidelines in this area. He points out that genetic testing for localized diagnosis in prostate cancer is still in its early stages across various cancer types, emphasizing the necessity for additional research to accumulate firm evidence and drive progress in the field.
  • 11.26.2023
    Adam B. Murphy, MD, MBA, MSCI, discusses a significant secondary discovery related to the impact of perceived patient health literacy on urologists' treatment decisions for prostate cancer. This insight is derived from the study titled "Impact of genomic testing on urologists' treatment preference in favorable risk prostate cancer: A randomized trial," where Dr. Murphy served as the senior author.
  • 11.10.2023
    Illinois state representative Lashawn Ford and Dr. Adam Murphy discuss the important of early detestion of prostate cancer and how facial hair is now being used to raise awareness for men's health specifically prostate cancer, testicular cancer and mental health. Movember is an annual initiative when men are encouraged to grow moustaches during the month of November.
  • 11.07.2023
    Adam B. Murphy, MD, MBA, MSCI, provides insights into the study titled "Impact of genomic testing on urologists' treatment preferences in favorable-risk prostate cancer: A randomized trial," in which he served as the senior author. He discusses the study's background and significant findings.
  • 10.23.2023
    Scientists have linked mutations in 11 genes with aggressive prostate cancer, according to the largest-ever study of its kind recently published in JAMA Oncology.
  • 10.16.2023

    Hormone replacement therapy (HRT) extends beyond women, as men also undergo changes in hormone levels, particularly a gradual decline in testosterone after age 30. While men don't experience a menopausal shift, factors like chronic conditions, including obesity and type 2 diabetes, can contribute to reduced testosterone levels. Robert Brannigan, MD explains the diagnosis of low testosterone, outlines symptoms and risk factors, and delves into available hormone therapy options for men, shedding light on potential risks associated with such treatments.

Follow the Lurie Cancer Center on

Follow the Department of Urology on